Mateon Therapeutics (OTCMKTS:MATN) versus Rapport Therapeutics (NASDAQ:RAPP) Financial Survey

Mateon Therapeutics (OTCMKTS:MATN) and Rapport Therapeutics (NASDAQ:RAPP) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their risk, analyst recommendations, profitability, valuation, dividends, institutional ownership and earnings.

Institutional & Insider Ownership

0.1% of Mateon Therapeutics shares are owned by institutional investors. 39.2% of Mateon Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Analyst Ratings

This is a summary of current recommendations for Mateon Therapeutics and Rapport Therapeutics, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Mateon Therapeutics	0	0	0	0	0.00
Rapport Therapeutics	0	0	3	0	3.00

Rapport Therapeutics has a consensus target price of $35.00, suggesting a potential upside of 53.24%. Given Rapport Therapeutics’ stronger consensus rating and higher possible upside, analysts clearly believe Rapport Therapeutics is more favorable than Mateon Therapeutics.

Profitability

This table compares Mateon Therapeutics and Rapport Therapeutics’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Mateon Therapeutics	N/A	-64.66%	-42.92%
Rapport Therapeutics	N/A	N/A	N/A

Earnings and Valuation

This table compares Mateon Therapeutics and Rapport Therapeutics”s top-line revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Mateon Therapeutics	N/A	N/A	-$6.64 million	N/A	N/A
Rapport Therapeutics	N/A	N/A	-$34.79 million	N/A	N/A

Summary

Rapport Therapeutics beats Mateon Therapeutics on 5 of the 8 factors compared between the two stocks.

About Mateon Therapeutics

Mateon Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in developing drugs for the treatment of orphan oncology indications. The company's lead product candidate is OT-101, an antisense against TGF-beta, which is in phase 3 clinical trials for pancreatic cancer and glioblastoma, as well as develops OT-101 for the treatment of various viruses, including severe acute respiratory syndrome and coronavirus. It also develops OXi4503 for the treatment of acute myeloid leukemia and myelodysplastic syndromes; and CA4P for the treatment of advanced metastatic melanoma. The company is headquartered in Agoura Hills, California.

About Rapport Therapeutics

Rapport Therapeutics Inc. is a clinical-stage biotechnology company. It focused on discovery and development of transformational small molecule medicines for patients suffering from central nervous system disorders. Rapport Therapeutics Inc. is based in BOSTON.